Affiliation:
1. Department of Neurology, GHU Paris Psychiatrie et Neurosciences Hôpital Sainte‐Anne, Université Paris Cité, INSERM U1266, and FHU Neurovasc Paris France
2. Department of Cardiology Hôpital Cochin, AP‐HP, Université Paris Cité Paris France
3. Department of Cardiology Hôpital Européen Georges Pompidou, AP‐HP, Université Paris Cité Paris France
Abstract
Background
Patent foramen ovale (PFO) is causally associated with stroke in some patients younger than 60 years, especially when it is large or associated with an atrial septal aneurysm (ASA). After 60 years of age, this association is less well understood. We assessed the relationships between detailed atrial septal anatomy and the cryptogenic nature of stroke in this population.
Methods and Results
We reviewed all patients aged 60 to 80 years admitted to our stroke center for ischemic stroke who underwent contrast echocardiography between 2016 and 2021. The atherosclerosis, small‐vessel disease, cardiac pathology, other causes, and dissection (ASCOD) classification was used to reevaluate the etiological workup. Associations between cryptogenic stroke and (1) PFO presence or (2) categories of PFO anatomy (nonlarge PFO without ASA, nonlarge PFO with ASA, large PFO without ASA, and large PFO with ASA) were assessed using logistic regression. Among 533 patients (median National Institutes of Health Stroke Scale score=1), PFO was present in 152 (prevalence, 28.5% [95% CI, 24.9–32.5]). Compared with noncryptogenic stroke, cryptogenic stroke (n=218) was associated with PFO presence (44.5% versus 17.5%;
P
<0.0001). Among patients with a PFO, septal anatomy categories were associated with cryptogenic stroke (
P
=0.02), with a strong association for patients with both large PFO and ASA (38.1% versus 14.5%,
P
=0.002).
Conclusions
PFO presence remains strongly associated with cryptogenic stroke between 60 and 80 years of age. Large PFO, ASA, and their association were strongly associated with cryptogenic stroke in this age group. Our results support performing contrast echocardiography even after 60 years of age, although the optimal secondary prevention therapy in this population remains to be determined in randomized trials.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献